It is item "Accelerated Approval", I would be interested in: see previous post: item 12.29.2
That could be given if there is a great advantage to the patient and it would be essential that the drug gets to market much quicker than usual.
One could argue that as EPT's Melanotan's action could reduce the risk of skin cancer, it therefore ought to be on the US market as soon as possible.
I am not sure if the FDA wil accept that argument; perhaps not but it is still worthwhile bringing it up here.
EPT people are not asleep and if they see an opening, they will use it, I think.
Just something of interest.
Gerry
5. data and comments. 5, page-2
-
- There are more pages in this discussion • 190 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add CUV (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$15.37 |
Change
0.130(0.85%) |
Mkt cap ! $770.0M | |||
| Open | High | Low | Value | Volume |
| $15.36 | $15.54 | $15.18 | $1.274M | 82.63K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 237 | $15.31 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $15.50 | 282 | 2 |
View Market Depth
| Last trade - 16.10pm 28/06/2024 (20 minute delay) ? |
| CUV (ASX) Chart |